-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
| Optogenetic therapy restores partial vision for blind people |
A patient who was diagnosed with retinitis pigmentosa nearly 40 years ago recovered part of his vision after receiving a new optogenetic therapy.
On May 24, this case study published by Nature Medicine is the first report of patients with neurodegenerative diseases who have recovered their function after receiving optogenetic therapy.
The researchers said that optogenetic therapy is to genetically modify specific cells to respond to light pulses, and then use light pulses to control these cells.
Retinitis pigmentosa is a neurodegenerative eye disease that destroys the photoreceptor cells of the retina and may lead to complete blindness in patients.
José Sahel and Botond Roska of the University of Pittsburgh, Pennsylvania, USA, and colleagues described the preliminary results of a phase 1/2a study that is still ongoing.
The researchers said that the patient tolerates the treatment well.
Experts say that optogenetic therapy may help restore visual function in patients with blindness associated with retinitis pigmentosa.
Related paper information: org/10.
org/10.
1038/s41591-021-01351-4" target="_blank">https://doi.
org/10.
1038/s41591-021-01351-4
